AR127501A1 - Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos - Google Patents
Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismosInfo
- Publication number
- AR127501A1 AR127501A1 ARP220102948A ARP220102948A AR127501A1 AR 127501 A1 AR127501 A1 AR 127501A1 AR P220102948 A ARP220102948 A AR P220102948A AR P220102948 A ARP220102948 A AR P220102948A AR 127501 A1 AR127501 A1 AR 127501A1
- Authority
- AR
- Argentina
- Prior art keywords
- phd
- inhibitors
- containing protein
- pharmaceutically acceptable
- prolyl hydroxylase
- Prior art date
Links
- 102000004079 Prolyl Hydroxylases Human genes 0.000 title 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000007502 anemia Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable, o estereoisómero del mismo. Reivindicación 43: Una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 - 42, o una sal farmacéuticamente aceptable, o estereoisómero del mismo, y un excipiente farmacéuticamente aceptable. Reivindicación 44: Un método para tratar una enfermedad o trastorno en un sujeto, el método comprende administrar al sujeto un compuesto de acuerdo con cualquiera de las reivindicaciones 1 - 42, o una sal farmacéuticamente aceptable, o estereoisómero del mismo, o una composición farmacéutica de acuerdo con la reivindicación 43, en donde la enfermedad o trastorno es anemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021127023 | 2021-10-28 | ||
| CN2022112270 | 2022-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127501A1 true AR127501A1 (es) | 2024-01-31 |
Family
ID=86159087
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102947A AR127500A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
| ARP220102948A AR127501A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
| ARP220102935A AR127488A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102947A AR127500A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102935A AR127488A1 (es) | 2021-10-28 | 2022-10-28 | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11731987B2 (es) |
| KR (2) | KR20240095274A (es) |
| CN (1) | CN118488838A (es) |
| AR (3) | AR127500A1 (es) |
| AU (1) | AU2022378858A1 (es) |
| CA (1) | CA3235718A1 (es) |
| IL (1) | IL312220A (es) |
| TW (3) | TW202332677A (es) |
| WO (3) | WO2023072257A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202301059D0 (en) | 2023-01-25 | 2023-03-08 | Univ Oxford Innovation Ltd | PHD inhibitors |
| CN117402178B (zh) * | 2023-12-15 | 2024-03-08 | 英矽智能科技(上海)有限公司 | 作为jak抑制剂和phd抑制剂的嘧啶类化合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6730682B2 (en) * | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| AU2003262946A1 (en) * | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| GB0505621D0 (en) * | 2005-03-18 | 2005-04-27 | Glaxo Group Ltd | Novel compounds |
| US8962530B2 (en) | 2007-06-27 | 2015-02-24 | Regents Of The University Of Colorado | Inflammatory bowel disease therapies |
| CA2696725A1 (en) * | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| EP2536709A4 (en) | 2010-02-17 | 2013-11-27 | Univ Cornell | PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE |
| EP2834220B1 (en) * | 2012-03-09 | 2016-11-09 | Fibrogen, Inc. | 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors |
| GB201504565D0 (en) | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| CN106146491B (zh) | 2015-03-27 | 2017-12-12 | 沈阳三生制药有限责任公司 | 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途 |
| CN106146490B (zh) | 2015-03-27 | 2018-10-23 | 沈阳三生制药有限责任公司 | 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途 |
| CN108341777A (zh) | 2017-01-23 | 2018-07-31 | 四川科伦博泰生物医药股份有限公司 | 异喹啉酮类化合物及其应用 |
| WO2018218042A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| TW201920108A (zh) * | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物 |
| SG11202002696VA (en) * | 2017-09-28 | 2020-04-29 | Nanjing Transthera Biosciences Co Ltd | Pde9 inhibitor and use thereof |
| CN110878096A (zh) | 2018-09-05 | 2020-03-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种1,7-萘啶类衍生物及其制备方法和用途 |
| CN112979541B (zh) | 2019-12-17 | 2022-11-11 | 浙江大学 | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 |
| AU2021219730A1 (en) * | 2020-02-12 | 2022-08-25 | Amgen Inc. | Novel PRMT5 inhibitors |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
-
2022
- 2022-10-28 WO PCT/CN2022/128293 patent/WO2023072257A1/en active Application Filing
- 2022-10-28 WO PCT/CN2022/128237 patent/WO2023072246A1/en unknown
- 2022-10-28 TW TW111141238A patent/TW202332677A/zh unknown
- 2022-10-28 AR ARP220102947A patent/AR127500A1/es unknown
- 2022-10-28 TW TW111141004A patent/TW202334134A/zh unknown
- 2022-10-28 CN CN202280086990.8A patent/CN118488838A/zh active Pending
- 2022-10-28 WO PCT/CN2022/128220 patent/WO2023072240A1/en active Application Filing
- 2022-10-28 KR KR1020247017207A patent/KR20240095274A/ko unknown
- 2022-10-28 AU AU2022378858A patent/AU2022378858A1/en active Pending
- 2022-10-28 KR KR1020247017209A patent/KR20240093899A/ko unknown
- 2022-10-28 AR ARP220102948A patent/AR127501A1/es unknown
- 2022-10-28 TW TW111141254A patent/TW202334158A/zh unknown
- 2022-10-28 CA CA3235718A patent/CA3235718A1/en active Pending
- 2022-10-28 AR ARP220102935A patent/AR127488A1/es unknown
- 2022-10-28 IL IL312220A patent/IL312220A/en unknown
-
2023
- 2023-02-15 US US18/110,259 patent/US11731987B2/en active Active
- 2023-02-15 US US18/110,261 patent/US11780854B2/en active Active
- 2023-08-31 US US18/240,886 patent/US20240067661A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022378858A1 (en) | 2024-05-02 |
| WO2023072240A1 (en) | 2023-05-04 |
| US20230192723A1 (en) | 2023-06-22 |
| IL312220A (en) | 2024-06-01 |
| TW202334134A (zh) | 2023-09-01 |
| TW202334158A (zh) | 2023-09-01 |
| US20240002406A1 (en) | 2024-01-04 |
| WO2023072257A1 (en) | 2023-05-04 |
| AR127500A1 (es) | 2024-01-31 |
| KR20240093899A (ko) | 2024-06-24 |
| CA3235718A1 (en) | 2023-05-04 |
| KR20240095274A (ko) | 2024-06-25 |
| AR127488A1 (es) | 2024-01-31 |
| CN118488838A (zh) | 2024-08-13 |
| US20240067661A1 (en) | 2024-02-29 |
| US11731987B2 (en) | 2023-08-22 |
| US20230192688A1 (en) | 2023-06-22 |
| TW202332677A (zh) | 2023-08-16 |
| WO2023072246A1 (en) | 2023-05-04 |
| US11780854B2 (en) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127501A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| CO2023000199A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| CL2023001476A1 (es) | Nuevos agentes antivirales derivados de la espiropirrolidina | |
| CO2023002852A2 (es) | Péptidos funcionalizados como agentes antivirales | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| CL2023003327A1 (es) | Inhibidores de la interaccion de menina-mll | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| CO2022002731A2 (es) | Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| ECSP22032016A (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| CO2023006808A2 (es) | Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| AR128932A1 (es) | Inhibidores de bcl-xl | |
| AR129171A1 (es) | Compuestos heteroaromáticos | |
| AR124000A1 (es) | Composición farmacéutica que comprende meloxicam | |
| AR128870A1 (es) | Inhibidores de tyk2 y usos de los mismos |